Showing results (421-430 of 439) with videos related to
Sort By:
Pageof 44
Anesthesia and Analgesia|September 13, 2021
Empowering Women as Leaders in Pediatric Anesthesiology: Methodology, Lessons, and Early Outcomes of a National InitiativeJamie McElrath Schwartz, Scott D Markowitz, Samuel D Yanofsky, et al.Implementation Science Communications|August 25, 2023
Using the RE-AIM framework to evaluate the implementation and effectiveness of a WHO HEARTS-based intervention to integrate the management of hypertension into HIV care in Uganda: a process evaluationMartin Muddu, Fred Collins Semitala, Isaac Derick Kimera, et al.Journal of Human Hypertension|February 1, 2024
Time to blood pressure control and predictors among patients receiving integrated treatment for hypertension and HIV based on an adapted WHO HEARTS implementation strategy at a large urban HIV clinic in UgandaWillington Amutuhaire, Fred Collins Semitala, Isaac Derick Kimera, et al.Platelets|April 30, 2011
The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirinAimee Dallob, Wen-Lin Luo, Julie Mabalot Luk, et al.The Journal of Clinical Endocrinology and Metabolism|August 1, 1996
Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in menJ I Schwartz, A Van Hecken, P J De Schepper, et al.The Journal of Pediatrics|August 30, 2021
Behavioral Health Diagnoses in Youth with Differences of Sex Development or Congenital Adrenal Hyperplasia Compared with Controls: A PEDSnet StudyRachel Sewell, Cindy L Buchanan, Shanlee Davis, et al.Journal of the International AIDS Society|July 7, 2025
Early findings from the integration of hypertension care into differentiated service delivery models for HIV in Uganda: a mixed-method studyJohn Baptist Kiggundu, Fred C Semitala, Chelsea Faith Lipoto, et al.Blood Cancer Journal|June 29, 2022
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering CommitteeShaji Kumar, Lawrence Baizer, Natalie S Callander, et al.Pharmacogenetics|May 8, 2001
In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokineticsC Tang, M Shou, T H Rushmore, et al.Journal of Clinical Pharmacology|March 18, 2003
Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in manNancy G B Agrawal, Arturo G Porras, Catherine Z Matthews, et al.Pageof 44